Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX

Key Points

• Dimensional Fund Advisors cut its Janux Therapeutics stake by 56.9% in the first quarter, selling 127,664 shares and retaining 96,630 shares worth approximately $1.34 million. Institutional investors collectively own 75.39% of JANX.
• Janux reported a quarterly loss of $0.35 per share, missing the $0.25 consensus estimate, while revenue of $10.27 million fell short of the $19.07 million forecast. Analysts expect a full-year loss of $1.76 per share.
• Analyst sentiment remains a “Moderate Buy,” with nine Buy, three Hold, and two Sell ratings and a consensus price target of $37.58, substantially above the stock’s recent $16.12 price.

Dimensional Fund Advisors LP lessened its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 56.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,630 shares of the company's stock after selling 127,664 shares during the quarter. Dimensional Fund Advisors LP owned 0.16% of Janux Therapeutics worth $1,343,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of JANX. Janus Henderson Group PLC lifted its position in shares of Janux Therapeutics by 13.8% during the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company's stock valued at $73,850,000 after purchasing an additional 649,341 shares in the last quarter. State Street Corp increased its position in shares of Janux Therapeutics by 103.8% during the fourth quarter. State Street Corp now owns 3,853,951 shares of the company's stock valued at $53,185,000 after acquiring an additional 1,962,486 shares during the last quarter. Vanguard Group Inc. boosted its position in Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company's stock worth $59,074,000 after purchasing an additional 227,676 shares during the last quarter. Prosight Management LP increased its position in shares of Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company's stock valued at $33,017,000 after purchasing an additional 1,527,173 shares during the last quarter. Finally, Orbimed Advisors LLC increased its position in shares of Janux Therapeutics by 10.7% during the 4th quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company's stock valued at $26,971,000 after purchasing an additional 188,326 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $16.12 on Friday. The firm has a market capitalization of $985.58 million, a P/E ratio of -9.83 and a beta of 2.50. The stock has a 50 day moving average price of $15.30 and a 200-day moving average price of $14.53. Janux Therapeutics, Inc. has a 52-week low of $12.12 and a 52-week high of $35.34.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The company had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.76 EPS for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the firm's stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider owned 75,941 shares of the company's stock, valued at approximately $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JANX. Piper Sandler reduced their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. Barclays downgraded Janux Therapeutics from an "overweight" rating to an "underweight" rating and decreased their target price for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Evercore set a $22.00 price target on Janux Therapeutics in a research report on Monday, May 11th. Stifel Nicolaus set a $35.00 price target on Janux Therapeutics in a research note on Friday, August 7th. Finally, Wedbush lowered their price objective on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $37.58.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source